FirstWord report: Branded versus generic drugs in Latin America

Home/Reports | Posted 08/03/2010

In the FirstWord report Branded vs. Generic Drugs in Latin America published in February 2010, it is stated that on every border, across every frontier of Latin America, a revolution is underway. Prefaced by the groundbreaking Hatch-Waxman Act of 1984, the war for market share between generic and branded pharmaceuticals is rapidly unfolding in Latin American countries from Brazil and Mexico to Ecuador and Cuba.

Developing biobetters through evergreening is ‘high value’

Home/Reports | Posted 24/02/2010

As reported by Subita Srimal in Mehta Perspectives on 6 January 2010, investment in biologics-based medicine is gaining momentum as these drugs offer targeted therapy and often safer treatment options, higher returns on investment and slower erosion of market share post patent expiry compared to small molecule-based drugs.

Mehta BioPharma Outlook 2010: Emerging markets not as attractive as they seem

Home/Reports | Posted 24/02/2010

As reported by Scrip, the emerging markets may not be as lucrative as they are being made out to be, at least in the short-term, and are expected to attain critical size only by around 2014, according to a new study by Mehta Partners.

How easily will Big Pharma slip into generics ‘avatar’?

Home/Reports | Posted 20/01/2010

After years of warding off generics, large pharmaceutical companies are embracing generic drug manufacturers and vying for a share of the off-patent drugs business. Indian generic companies, once considered business pariahs, are the focus of plenty of action, Anju Ghangurde reports in Scrip News of 9 December 2009.

FirstWord report: Biobetters as solution for biosimilars

Home/Reports | Posted 14/01/2010

In December 2009, FirstWord published the new report Biobetters - Major Players and Market Prospects on the challenging field of biobetters.

European drug seizures criticised in Oxfam/HAI report

Home/Reports | Posted 12/01/2010

EU trade policies regulating the pharmaceutical industry, including the seizure of generic drugs in transit to developing countries, are supporting the commercial interests of some drugmakers while damaging opportunities for innovation and access to medicines in developing countries, an Oxfam International and Health Action International (HAI) report says. The report criticizes recent European customs authorities’ seizures of generic drugs suspected of infringing intellectual property rights.

The world market for biosimilars and their potential in the US

Home/Reports | Posted 26/10/2009

Kalorama Information published a new report on biosimilars, World Market for Biosimilars and the Potential for US Follow-on Biologics on 1 August 2009, based on interviews in the ‘biogeneric’ drug industry and an extensive literature study.

Accenture report: biosimilars offer chances despite risks

Home/Reports | Posted 19/10/2009

According to the report Biosimilars – Emergence of a third market dynamic between original products and generics published by the global management consultancy, Accenture, the biosimilars market will open up interesting opportunities for pharmaceutical and generic companies despite significant risks.

Emerging market for biosimilars and biobetters

Home/Reports | Posted 14/10/2009

The Biophoenix report Biosimilars and Biobetters: Positioning for a New Market published on 9 July 2009 reveals that biosimilar sales may reach US$6 billion (Euros 4.2 billion) by 2013 as regulatory frameworks take shape.

EU will act against drugmakers that delay generics

Home/Reports | Posted 30/09/2009

The European Commission (EC) released its final report on 8 July 2009 concerning competition in the pharmaceutical sector, and said it will increase its oversight of the industry after finding that drugmakers' business practices contributed to the delay of generic drugs being introduced to the market. The EC explained that “to reduce the risk that settlements between originator and generic companies are concluded at the expense of consumers, the EC undertakes to carry out further focused monitoring of settlements that limit or delay the market entry of generic drugs”. Furthermore, it will not hesitate to act against ‘anticompetitive practices’ by drugmakers that delay the market entry of generics, but has also called on Member States to do more to boost generic uptake.